Section Arrow
IRON.NASDAQ
- Disc Medicine
Quotes are at least 15-min delayed:2025/04/14 02:23 EDT
Last
 38.73
+3.5 (+9.93%)
Day High 
39.26 
Prev. Close
35.23 
1-M High
56.29 
Volume 
549.56K 
Bid
15.5
Ask
38.73
Day Low
35.04 
Open
35.23 
1-M Low
30.82 
Market Cap 
1.22B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 43.21 
20-SMA 47.89 
50-SMA 51.98 
52-W High 68.73 
52-W Low 25.6435 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.96/-3.98
Enterprise Value
1.25B
Balance Sheet
Book Value Per Share
12.83
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals5.76+1.25+27.72%-- 
THTXTheratechnologies1.94+0.61+45.86%-- 
CDTConduit Pharmaceuticals Inc0.9101-0.1599-14.94%-- 
PRTGPortage Biotech Inc8.59+3.49+68.43%0.17PE
HEPAHepion Pharmaceuticals0.422-0.0091-2.11%-- 
Quotes are at least 15-min delayed:2025/04/14 02:23 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.